AI drug-discovery startup Pathos AI has raised $237 million in a Series E funding round led by Bristol Myers Squibb, valuing the New York-based company at about $3 billion. The financing landed alongside a three-way collaboration that will put Pathos’s artificial intelligence platform to work on Alzheimer’s disease and other neurological disorders, with Bristol Myers and the health-data company Tempus AI.
Pathos AI said on Friday that the round drew participation from existing investors, on top of the new money led by Bristol Myers. The raise makes it one of the largest AI-for-drug-discovery financings of the month, and it cements a bet by a major pharmaceutical company on machine learning as the engine of its neuroscience pipeline.
The $237 Million Round And The $3 Billion Valuation
The financing was led by Bristol Myers Squibb itself — an unusual structure for a biotech raise, where a pharma strategic leads rather than joins. Pathos said proceeds will be used to scale the capabilities of its Pathos Foundry platform and to accelerate its AI-driven drug pipeline, including an experimental cancer drug called JSKN016 and a second cancer program developed with AstraZeneca, an experimental breast cancer drug partnered with the British-Swedish pharma giant.
The round is not Pathos’s first brush with the industry’s biggest players. The company has been building Foundry as a single system that moves from disease biology to clinical trial design, and the new capital is aimed squarely at scaling that engine rather than starting new programs from scratch.
How The Collaboration Works: Data, Platform, Exclusivity
The partnership divides the work three ways. Tempus AI will build a dataset drawn from hundreds of thousands of patients with neurological disorders, designed to track outcomes and speed research into disease biology. Pathos will license that data from Tempus under a five-year, $55 million agreement — a reminder of how valuable annotated patient data has become in the AI era.
Pathos then applies its Foundry platform to the dataset at scale: generating and testing hypotheses about disease biology, and informing the design of more targeted, adaptive clinical trials. In exchange, Bristol Myers gains non-exclusive strategic access to Pathos Foundry across its broader portfolio, plus three-year exclusive rights to use the platform for its neuroscience development programs.
What The Money And The Deals Build
Taken together, the announcement is really two stories. The first is a classic financing: $237 million at a ~$3 billion valuation to scale an AI platform and advance a cancer pipeline. The second is a deeper integration of AI into drug development — a dataset built specifically for machine learning, a licensing deal that prices the data at $55 million over five years, and a pharma giant locking up exclusive rights to an AI platform for its entire neuroscience franchise.
The Alzheimer’s focus is notable. Neurological diseases have one of the highest failure rates in clinical trials, and drug developers have been hunting for better ways to identify which patients will respond to a treatment before a trial begins. Pathos is pitching Foundry as the system that finds those signals in patient data at a scale no human team could match.
Why It Matters
The Pathos deal is a sign of where the AI drug-discovery industry is heading. The first generation of these companies sold their models to pharma as services; the second is getting pharma to fund them as partners and take equity stakes in the outcome. Bristol Myers leading a $237 million round — rather than just signing a collaboration — is a vote of confidence in AI-designed drugs that is hard to read any other way.
It also shows how the industry’s bottleneck has shifted. Five years ago, the pitch was better algorithms. Today, with Pathos paying Tempus $55 million for access to patient data, the pitch is better data — and the companies that can assemble, license and mine hundreds of thousands of patient records are the ones commanding three-billion-dollar valuations.
Background
AI-driven drug discovery has become one of the busiest corners of the AI startup economy, with Warp Sciences emerging from stealth with $215 million to automate drug chemistry just this week and Electric Plant raising $11.2 million to build a foundation model that reads plant biology. Pathos AI, based in New York, has positioned itself around its Foundry platform, which applies machine learning across disease biology research and clinical trial design — the same full-stack approach investors have rewarded across the sector in 2026.
Source: Reuters
0 Comments